SPRO logo

Spero Therapeutics (SPRO) EBITDA

Annual EBITDA

$25.77 M
+$68.71 M+160.01%

December 31, 2023

Summary

Performance

1-Year Change

+160.01%

3-Year Change

+133.24%

5-Year Change

+160.78%

15-Year Change

+162.3%

SPRO EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

83.49%
SPRO annual EBITDA is higher than 83.49% of companies in Healthcare sector

High & Low

All-time High

$25.77 M
SPRO annual EBITDA is currently at an all-time high

3-Year Low

-$87.17 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
SPRO previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 13, 2025
SPRO next annual earnings announcement is scheduled for Mar 13, 2025

OtherSPROprofitabilitymetrics:

Annual Revenue

$96.73 M
SPRO annual revenue is $96.73 million

Annual Net Income

$22.81 M
SPRO annual net profit is $22.81 million

Annual EBIT

$25.40 M
SPRO annual earnings before interest & taxes is $25.40 million

Annual EPS

$0.43
SPRO annual earnings per share is $0.43

Quarterly EBITDA

-$18.59 M
+$466.00 K+2.45%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

-137.8%

3-Year Change

-137.8%

5-Year Change

-137.8%

SPRO Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

24.6%
SPRO quarterly EBITDA is higher than 24.6% of companies in Healthcare sector

High & Low

All-time High

$49.19 M
SPRO quarterly EBITDA is currently -137.80% below its historical high of $49.19 million

3-Year Low

-$30.15 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
SPRO previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 13, 2025
SPRO next earnings announcement is scheduled for Mar 13, 2025

OtherSPROprofitabilitymetrics:

Quarterly Revenue

$7.82 M
SPRO quarterly revenue is $7.82 million

Quarterly Net Income

-$17.15 M
SPRO quarterly net profit is -$17.15 million

Quarterly EBIT

-$18.59 M
SPRO quarterly earnings before interest & taxes is -$18.59 million

Quarterly EPS

-$0.32
SPRO quarterly earnings per share is -$0.32

TTM EBITDA

-$2.45 M
-$22.07 M-112.47%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

-109.5%

3-Year Change

-109.5%

5-Year Change

-109.5%

SPRO TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

74.22%
SPRO TTM EBITDA is higher than 74.22% of companies in Healthcare sector

High & Low

All-time High

$25.90 M
SPRO TTM EBITDA is currently -109.45% below its historical high of $25.90 million

3-Year Low

-$107.91 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
SPRO previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 13, 2025
SPRO next earnings announcement is scheduled for Mar 13, 2025

OtherSPROprofitabilitymetrics:

TTM Revenue

$89.86 M
SPRO TTM revenue is $89.86 million

TTM Net Income

$3.51 M
SPRO TTM net profit is $3.51 million

TTM EBIT

-$2.49 M
SPRO TTM earnings before interest & taxes is -$2.49 million

TTM EPS

$0.08
SPRO TTM earnings per share is $0.08

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

$25.77 M
SPRO annual EBITDA is $25.77 million

Annual Net Income

$22.81 M
SPRO annual net profit is $22.81 million

Annual Interest Expense

$0.00
SPRO annual interest expense is $0.00

Annual Income Tax

$2.60 M
SPRO annual income tax is $2.60 million

Annual D&A

$367.00 K
SPRO annual depreciation & amortization is $367.00 thousand

SPRO EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+160.0%-137.8%-109.5%
3 y3 years+133.2%-137.8%-109.5%
5 y5 years+160.8%-137.8%-109.5%

SPRO EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+129.6%-137.8%+38.3%-109.5%+97.7%
5 y5-yearat high+129.6%-137.8%+38.3%-109.5%+97.7%
alltimeall timeat high+129.6%-137.8%+38.3%-109.5%+97.7%

Spero Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$18.59 M(-2.4%)
-$2.45 M(-112.5%)
Jun 2024
-
-$19.06 M(+36.3%)
$19.63 M(-24.2%)
Mar 2024
-
-$13.98 M(-128.4%)
$25.90 M(+0.5%)
Dec 2023
$25.77 M(-160.0%)
$49.19 M(+1313.4%)
$25.77 M(+639.7%)
Sep 2023
-
$3.48 M(-127.2%)
$3.48 M(-130.5%)
Jun 2023
-
-$12.78 M(-9.4%)
-$11.41 M(-57.6%)
Mar 2023
-
-$14.11 M(-152.5%)
-$26.90 M(-37.3%)
Dec 2022
-$42.94 M(-50.7%)
$26.90 M(-335.6%)
-$42.94 M(-55.7%)
Sep 2022
-
-$11.42 M(-59.6%)
-$96.95 M(-10.2%)
Jun 2022
-
-$28.27 M(-6.2%)
-$107.91 M(+10.0%)
Mar 2022
-
-$30.15 M(+11.2%)
-$98.06 M(+12.5%)
Dec 2021
-$87.17 M(+12.4%)
-$27.11 M(+21.2%)
-$87.17 M(+12.0%)
Sep 2021
-
-$22.37 M(+21.4%)
-$77.83 M(+4.8%)
Jun 2021
-
-$18.42 M(-4.4%)
-$74.29 M(+0.2%)
Mar 2021
-
-$19.26 M(+8.4%)
-$74.15 M(-4.3%)
Dec 2020
-$77.52 M
-$17.77 M(-5.6%)
-$77.52 M(-9.5%)
Sep 2020
-
-$18.83 M(+3.0%)
-$85.63 M(+1.6%)
DateAnnualQuarterlyTTM
Jun 2020
-
-$18.29 M(-19.2%)
-$84.30 M(+6.1%)
Mar 2020
-
-$22.63 M(-12.6%)
-$79.47 M(+27.5%)
Dec 2019
-$62.47 M(+47.3%)
-$25.88 M(+47.9%)
-$62.35 M(+31.5%)
Sep 2019
-
-$17.50 M(+29.9%)
-$47.42 M(+16.3%)
Jun 2019
-
-$13.46 M(+144.3%)
-$40.77 M(+9.6%)
Mar 2019
-
-$5.51 M(-49.6%)
-$37.19 M(-12.3%)
Dec 2018
-$42.40 M(+2.5%)
-$10.95 M(+0.8%)
-$42.40 M(-6.5%)
Sep 2018
-
-$10.85 M(+9.9%)
-$45.35 M(+2.2%)
Jun 2018
-
-$9.88 M(-7.9%)
-$44.37 M(-0.5%)
Mar 2018
-
-$10.72 M(-22.9%)
-$44.58 M(+11.0%)
Dec 2017
-$41.37 M(+25.6%)
-$13.90 M(+40.8%)
-$40.17 M(+14.8%)
Sep 2017
-
-$9.87 M(-2.1%)
-$34.99 M(+6.2%)
Jun 2017
-
-$10.08 M(+59.7%)
-$32.96 M(+44.1%)
Mar 2017
-
-$6.31 M(-27.6%)
-$22.88 M(+38.1%)
Dec 2016
-$32.94 M(+147.4%)
-$8.72 M(+11.3%)
-$16.57 M(+111.3%)
Sep 2016
-
-$7.84 M
-$7.84 M
Dec 2015
-$13.32 M
-
-

FAQ

  • What is Spero Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Spero Therapeutics?
  • What is Spero Therapeutics annual EBITDA year-on-year change?
  • What is Spero Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Spero Therapeutics?
  • What is Spero Therapeutics quarterly EBITDA year-on-year change?
  • What is Spero Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Spero Therapeutics?
  • What is Spero Therapeutics TTM EBITDA year-on-year change?

What is Spero Therapeutics annual EBITDA?

The current annual EBITDA of SPRO is $25.77 M

What is the all time high annual EBITDA for Spero Therapeutics?

Spero Therapeutics all-time high annual EBITDA is $25.77 M

What is Spero Therapeutics annual EBITDA year-on-year change?

Over the past year, SPRO annual EBITDA has changed by +$68.71 M (+160.01%)

What is Spero Therapeutics quarterly EBITDA?

The current quarterly EBITDA of SPRO is -$18.59 M

What is the all time high quarterly EBITDA for Spero Therapeutics?

Spero Therapeutics all-time high quarterly EBITDA is $49.19 M

What is Spero Therapeutics quarterly EBITDA year-on-year change?

Over the past year, SPRO quarterly EBITDA has changed by -$67.78 M (-137.80%)

What is Spero Therapeutics TTM EBITDA?

The current TTM EBITDA of SPRO is -$2.45 M

What is the all time high TTM EBITDA for Spero Therapeutics?

Spero Therapeutics all-time high TTM EBITDA is $25.90 M

What is Spero Therapeutics TTM EBITDA year-on-year change?

Over the past year, SPRO TTM EBITDA has changed by -$28.22 M (-109.50%)